| (19) |
 |
|
(11) |
EP 3 381 452 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 2 (W2 A1) |
| (48) |
Corrigendum issued on: |
|
12.12.2018 Bulletin 2018/50 |
| (43) |
Date of publication: |
|
03.10.2018 Bulletin 2018/40 |
| (22) |
Date of filing: 31.03.2017 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
|
Designated Validation States: |
|
MA MD |
| (71) |
Applicants: |
|
- Instituto Catalán de Ciencias Cardiovasculares
(ICCC), Hospital de la Santa Creu i Sant Pau,
Avda.
08025 Barcelona (ES)
- Gendiag, S.L.
08950 Esplugues de Llobregat (Barcelona) (ES)
|
|
| (72) |
Inventors: |
|
- Badimon, Lina
08025 Barcelona (ES)
- Vilahur, Gemma
08025 Barcelona (ES)
|
| (74) |
Representative: Hoffmann Eitle |
|
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München
81925 München (DE) |
|
| |
|
| (54) |
STATIN FOR PREVENTION/REDUCTION OF ISCHEMIA-RELATED DAMAGE |
(57) The present disclosure relates, in general, to the prevention and/or reduction of
ischemia-related damage. More specifically, the present disclosure relates to compounds
for use in the prevention and/or reduction of ischemia-related damage. The compounds
are statins.